VeriMom¿Es tasmannia lanceolata leaf extract seguro durante el embarazo?
No harmonised CLP reproductive classification (ECHA Annex VI) or SCCS/CIR safety assessment was identified for Tasmannia lanceolata leaf extract. A search of peer‑reviewed literature (PubMed) yields no controlled reproductive or developmental toxicity studies implicating this botanical; dominant constituents (e.g., polygodial) are described for irritancy/antimicrobial activity but not for teratogenicity. Therefore default hazard/mechanism scores are 0 and expected exposure from topical cosmetic use is low (e=0). Sources: ECHA Annex VI (no harmonised CLP entry), PubMed, CosIng, PubChem.
Pregnancy-safe products containing tasmannia lanceolata leaf extract
Related ingredients
Frequently asked questions
- ¿Es tasmannia lanceolata leaf extract seguro durante el embarazo?
- No harmonised CLP reproductive classification (ECHA Annex VI) or SCCS/CIR safety assessment was identified for Tasmannia lanceolata leaf extract. A search of peer‑reviewed literature (PubMed) yields no controlled reproductive or developmental toxicity studies implicating this botanical; dominant constituents (e.g., polygodial) are described for irritancy/antimicrobial activity but not for teratogenicity. Therefore default hazard/mechanism scores are 0 and expected exposure from topical cosmetic use is low (e=0). Sources: ECHA Annex VI (no harmonised CLP entry), PubMed, CosIng, PubChem.
- ¿Es tasmannia lanceolata leaf extract seguro durante la lactancia?
- No evidence in regulatory sources or peer‑reviewed literature of lactation-specific risks or transfer via breast milk for this ingredient. No harmonised classifications or CIR/SCCS opinions raising reproductive/lactational concerns. Topical cosmetic exposure is expected to be low for mother (e=0). Sources: PubMed, CosIng, ECHA Annex VI.
- ¿Es tasmannia lanceolata leaf extract seguro para la piel del bebé?
- No infant‑specific reproductive or developmental toxicity data found. Hazard and mechanism remain 0 due to absence of evidence of reproductive/ED effects. Exposure score increased by +1 (e=1) for 0–3‑year‑old skin because infant barrier immaturity increases potential percutaneous uptake relative to adults and because the ingredient is not an inherently non‑absorbable mineral; however, no data quantify neonatal absorption. Note: known concerns for this extract are primarily topical irritancy/allergenicity (from compositional constituents such as polygodial) rather than reproductive toxicity. Sources: PubMed, CosIng, EWG.
- ¿Cómo puntúa VeriMom a tasmannia lanceolata leaf extract?
- VeriMom puntúa tasmannia lanceolata leaf extract en 100/100 (sin riesgos conocidos) según el estado EU CosIng, clasificaciones ECHA y estudios PubMed.
- ¿Cuáles son las alternativas seguras a tasmannia lanceolata leaf extract en el embarazo?
- Consulta nuestra lista de alternativas seguras a tasmannia lanceolata leaf extract según función similar y clasificación sin riesgos conocidos.
Comprueba cualquier etiqueta en 2 segundos
Descarga VeriMom gratis — escanea cualquier producto y ve la puntuación de seguridad en el embarazo al instante.
Aviso Médico
Esta información es solo para fines educativos y no constituye asesoramiento médico. Las puntuaciones de seguridad se basan en datos disponibles públicamente y pueden no reflejar todos los riesgos. Siempre consulte a su profesional de salud antes de usar cualquier producto durante el embarazo o la lactancia.